Who makes Ketamine first AB?

Ketamine first AB is developed by Tampere University Hospital.

What development phase is Ketamine first AB in?

Ketamine first AB is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Ketamine first AB

Tampere University Hospital · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Ketamine first AB
Also known as	S(+)-ketamine
Sponsor	Tampere University Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome. (NA)
Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ketamine first AB CI brief — competitive landscape report
Ketamine first AB updates RSS · CI watch RSS
Tampere University Hospital portfolio CI